Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Elanco Animal Health GmbH has 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 6 distinct examiners. This distribution shows that no single examiner is currently managing more than 1 matter for the company, which may facilitate a focused review of each individual application. The use of multiple examiners across the portfolio ensures that the prosecution is not dependent on the tendencies of a single individual.
The portfolio involves 4 distinct art units. Since there are more examiners than the 4 distinct art units, some units are reviewing multiple applications for the company. This overlap within art units suggests that the technical subject matter is concentrated within specific divisions of the patent office. KIM, SEONG JONG is the busiest examiner, with 1 pending office action. This workload is consistent with the other examiners assigned to the portfolio, maintaining an even balance of responsibility across the active cases.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (14%) |
| Double-patenting + other | 3 (43%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, SEONG JONG | 1 | 25.0% | +0.0% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
| RAHMAN, MASUDUR | 1 | 72.7% | +31.7% |
| MORGAN, BAILEY MICHELLE | 1 | 56.3% | +58.3% |
| HEITMEIER, KENDALL NICOLE | 1 | 65.9% | +41.0% |
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.8% |
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002928 | NOVEL HETEROARYL-SUBSTITUTED PYRAZINE DERIVATIVES AS PESTICIDES | HEITMEIER, KENDALL NICOLE | 3d overdue |
| 18366306 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES | RAHMAN, MASUDUR | 34d |
| 18730668 | MOLIDUSTAT FORMULATIONS AND METHODS OF USE FOR TREATMENT OF ANEMIA IN CATS | KIM, SEONG JONG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002928 | NOVEL HETEROARYL-SUBSTITUTED PYRAZINE DERIVATIVES AS PESTICIDES | HEITMEIER, KENDALL NICOLE | 3d overdue |
| 18366306 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES | RAHMAN, MASUDUR | 34d |
| 18262949 | VACCINE COMPOSITION FOR BREAKING SELF-TOLERANCE | MORGAN, BAILEY MICHELLE | — |
| 17771732 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | RODRIGUEZ-GARCIA, VALERIE | — |
| 17767018 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | NESTOR, DONNA MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| 1623 | 1 |
| 1633 | 1 |
| 1645 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18730668 | MOLIDUSTAT FORMULATIONS AND METHODS OF USE FOR TREATMENT OF ANEMIA IN CATS | KIM, SEONG JONG | — | §102§103§112 | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18690087 | NEW QUINOLINE DERIVATIVES | SHTERENGARTS, SAMANTHA L | 1623 | §102DP | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18366306 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES | RAHMAN, MASUDUR | 1633 | §103§112 | Non-Final OA | 34d | Pending | Aug 07, 2023 |
| 18262949 | VACCINE COMPOSITION FOR BREAKING SELF-TOLERANCE | MORGAN, BAILEY MICHELLE | 1645 | §103§112DP | Non-Final OA | — | Pending | Jul 26, 2023 |
| 18002928 | NOVEL HETEROARYL-SUBSTITUTED PYRAZINE DERIVATIVES AS PESTICIDES | HEITMEIER, KENDALL NICOLE | 1621 | §102§103§112Other | Final Rejection | 3d overdue | Pending | Dec 22, 2022 |
| 17771732 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | RODRIGUEZ-GARCIA, VALERIE | 1621 | §112 | Non-Final OA | — | Pending | Apr 25, 2022 |
| 17767018 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | NESTOR, DONNA MICHELLE | 1627 | §103§112DP | Final Rejection | — | Pending | Apr 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial